

**The use of stems in the selection of
International Nonproprietary Names (INN)
for pharmaceutical substances**

2013



The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances

2013



International Nonproprietary Names (INN) Programme
Technologies Standards and Norms (TSN)
Regulation of Medicines and other Health Technologies (RHT)
Essential Medicines and Health Products (EMP)

**The use of stems in the selection of International Nonproprietary Names
(INN) for pharmaceutical substances**

FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15

© World Health Organization 2013

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

PREFACE

The document *"The Use of Common Stems in the Selection of INNs"* is intended primarily for persons and companies applying to the WHO INN Programme for the selection of an INN for a new pharmaceutical substance and has been designed to assist in the process of devising a suitable proposal. It will also be of assistance to institutions and specialists involved in the review of proposed INNs, including drug regulatory authorities, pharmaceutical manufacturers, patent offices and trade mark officers as well as for scientists, teachers, health professionals and other persons interested generally in drug nomenclature. The document is composed of four main parts and annexes.

Part I *"Introduction"* describes the WHO INN Programme, INN selection procedure, and criteria for name selection and gives general information on the INN stem system.

Part II contains the list of all INN stems. It is composed of two indexes, one entitled *"Alphabetical List of Common Stems"* which presents the list of stems, and another entitled *"Alphabetical List of Common Stems and their definitions"* which includes a definition for each stem.

Part III presents the stem classification system used by the INN Programme to categorize the main activity of pharmaceutical substances. Each category included in the list is given an appropriate code consisting of a capital letter and three digits. When INNs for substances belonging to a given category include a specific stem, appropriate information is included in the table.

Part IV of the document entitled *"Alphabetical List of Stems Together With Corresponding INNs"* serves as a listing of all proposed INNs (published in lists 1 - 109) containing INN stems. The list is organized in alphabetical order (as set out in Part II) and includes all INNs containing individual stems. In addition, under each stem heading information is given on INNs in which the preferred stem has been used but not in accordance with its definition as well as on INNs which belong to the same group of pharmaceutical substances but in which no preferred stem has been used. To facilitate the use of Part IV, the lay-out of information is presented as a diagram on page 6 and is complemented by additional information given at the end of part I *"Introduction"*.

Six annexes attached to the document are intended to be of assistance to users. Annex 1 reproduces the *Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* as approved by the WHO Executive Board in its resolution EB15.R7 as amended by resolution EB115.R4. Annex 2 reproduces *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* as approved by the WHO Executive Board in the above-mentioned resolution, as amended. Annex 3 explains the nomenclature scheme for monoclonal antibodies. Annex 4 explains the nomenclature scheme for Gene Therapy Products. Annex 5 gives reference to the volumes of the *WHO Drug Information* in which proposed lists of INNs have been published. Annex 6 *"Why INN?"* gives general information on the present situation of WHO INN Programme and its achievements.

TABLE OF CONTENTS

	<i>Pages</i>
Table of contents	3
Part I Introduction	5 - 7
Part II A. Alphabetical list of common stems	9 – 12
Part II B. Alphabetical list of common stems and their definition	13 - 32
Part III Stem classification with corresponding examples of stems and their definition	33 – 60
Part IV Alphabetical list of stems together with corresponding INNs	61- 173
Annex 1 Procedure for the selection of Recommended INNs for Pharmaceutical Substances	175 – 178
Annex 2 General Principles for Guidance in Devising INNs for Pharmaceutical Substances	179 – 180
Annex 3 INN stems for monoclonal antibodies	181 – 182
Annex 4 INNs for Gene Therapy Products	183
Annex 5 Reference to publications containing proposed lists of INNs	184
Annex 6 Why INNs ?	185

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28285

